Built to Last Beyond the Trial? Real World Treatment Durability in Psoriatic Disease PsA cover art

Built to Last Beyond the Trial? Real World Treatment Durability in Psoriatic Disease PsA

Built to Last Beyond the Trial? Real World Treatment Durability in Psoriatic Disease PsA

Listen for free

View show details
🎙️ 💡 When Skin and Joints Actually Mean… Skin AND Joints In this episode of the Skin and Joints Podcast, we bring together two expert voices — dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem— for a true cross-specialty conversation on psoriatic arthritis care. The focus? 🔍 The recent PRO-SPIRIT 12-month real-world study exploring the comparative effectiveness and persistence biologic/targeted synthetic DMARDs in patients with PsA. And spoiler alert 🚨: this isn’t just another “good skin drug vs good joint drug” debate. We dive into what the data means when the patient in front of you has plaques, pain, fatigue, stiffness, nail disease, possible axial symptoms, quality-of-life concerns… and a very real desire to just feel like themselves again. What demonstrated a balanced signal across both skin and joint domains? ✅Dr. Hong brings the dermatology lens: clearing skin matters deeply, and identifying PsA early can change the entire treatment pathway. ✅Dr. Kazem brings the rheumatology lens: PsA is heterogeneous, patient-reported outcomes matter, and treatment decisions need to account for competing domains like GI disease, uveitis, axial symptoms, and inflammatory arthritis burden. ✅Together, they remind us why PsA care works best when dermatology and rheumatology stop playing telephone ☎️ and start sitting at the same table. Preferably with coffee ☕. Possibly with a “skin and joints” drinking game. 🎧 Tune in for a practical, witty, and clinically grounded conversation on how real-world data can help refine real-world decisions. 🎯 Learning Objectives: After listening to this episode, learners will be able to: Describe the clinical relevance of the 12-month PRO-SPIRIT real-world study evaluating b/tsDMARDs in PsA.Discuss how dermatology and rheumatology perspectives differ — and overlap — when selecting advanced therapies for PsA.Identify key limitations of real-world comparative effectiveness studies, including confounding by indication and baseline phenotype differences.Apply a phenotype-driven approach to treatment selection across skin, joint, axial, enthesitis, nail, GI, and uveitis domains.Recognize the importance of repeat PsA screening in patients with psoriasis and the role of multidisciplinary co-management.Interpret treatment persistence and patient-reported outcomes in the context of real-world clinical practice. #SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast Episode supported by and IME Grant from Eli Lilly. ABOUT Dr. Chih-ho Hong, MD, FRCPC Dermatologist, Vancouver, BC Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination. He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses. ABOUT Dr. May Kazem, MD, FRCPC Rheumatologist, Vancouver, BC Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship training at the Schulich School of Medicine at Western University. Dr. Kazem practices general rheumatology in Vancouver and her areas of interest include management of patients with various inflammatory rheumatologic disorders and complex osteoporosis. She is also actively involved in medical education and patient advocacy, to promote awareness, knowledge-sharing, and improved care for individuals living with rheumatic conditions. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca 📻www.skinandjoints.ca✉️info@skinandjoints.ca
adbl_web_anon_alc_button_suppression_t1
No reviews yet